214 related articles for article (PubMed ID: 11060684)
1. A review of clinical trials with fluoroquinolones with an emphasis on new agents.
Blondeau JM
Expert Opin Investig Drugs; 2000 Feb; 9(2):383-413. PubMed ID: 11060684
[TBL] [Abstract][Full Text] [Related]
2. Clinical utility of the new fluoroquinolones for treating respiratory and urinary tract infections.
Blondeau JM
Expert Opin Investig Drugs; 2001 Feb; 10(2):213-37. PubMed ID: 11178338
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of sparfloxacin in comparison with currently available antimicrobials against respiratory tract pathogens.
Baquero F; Cantón R
J Antimicrob Chemother; 1996 May; 37 Suppl A():1-18. PubMed ID: 8737121
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin and sparfloxacin: new quinolone antibiotics.
Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
[TBL] [Abstract][Full Text] [Related]
5. Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
Pechère JC; Gootz TD
Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):405-12. PubMed ID: 9758283
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics.
Nightingale CH
Pharmacotherapy; 2000 Mar; 20(3):245-56. PubMed ID: 10730681
[TBL] [Abstract][Full Text] [Related]
7. Two new fluoroquinolones.
Med Lett Drugs Ther; 1992 Jun; 34(872):58-60. PubMed ID: 1317502
[No Abstract] [Full Text] [Related]
8. Fluoroquinolones.
O'Donnell JA; Gelone SP
Infect Dis Clin North Am; 2000 Jun; 14(2):489-513, xi. PubMed ID: 10829268
[TBL] [Abstract][Full Text] [Related]
9. [Activities of antimicrobial agents against 5,180 clinical isolates obtained from 26 medical institutions during 1998 in Japan. Levofloxacin--Surveillance Group].
Yamaguchi K; Miyazaki S; Kashitani F; Iwata M; Kanda M; Tsujio Y; Okada J; Tazawa Y; Watanabe N; Uehara N; Igari J; Oguri T; Kaimori M; Kawamura C; Iinuma Y; Nisawataira T; Tashiro H; Ueno K; Ishigo S; Yasujima M; Kawahara S; Itoh C; Yoshida T; Yamanaka K; Toyoshima S; Katoh J; Kudoh M; Matsushima T; Niki Y; Miyashita N; Funato T; Kaku M; Sato N; Saito Y; Ishii K; Kuwabara M; Hongo T; Negayama K; Kamihira S; Miyazaki Y; Takii M; Ishii M; Nakagawa K; Ono J; Takada T; Murakami N; Taira M; Tamaki I; Matsudou Y; Nakasone I
Jpn J Antibiot; 2000 Jun; 53(6):387-408. PubMed ID: 10955236
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program.
Jones RN; Pfaller MA
Clin Infect Dis; 2000 Aug; 31 Suppl 2():S16-23. PubMed ID: 10984323
[TBL] [Abstract][Full Text] [Related]
11. Expanded activity and utility of the new fluoroquinolones: a review.
Blondeau JM
Clin Ther; 1999 Jan; 21(1):3-40; discussion 1-2. PubMed ID: 10090423
[TBL] [Abstract][Full Text] [Related]
12. Microbiology of newer fluoroquinolones: focus on respiratory pathogens.
Jones RN
Diagn Microbiol Infect Dis; 2002 Nov; 44(3):213-20. PubMed ID: 12493166
[TBL] [Abstract][Full Text] [Related]
13. A critical review of the fluoroquinolones: focus on respiratory infections.
Zhanel GG; Ennis K; Vercaigne L; Walkty A; Gin AS; Embil J; Smith H; Hoban DJ
Drugs; 2002; 62(1):13-59. PubMed ID: 11790155
[TBL] [Abstract][Full Text] [Related]
14. Zabofloxacin for chronic bronchitis.
Kocsis B; Szabo D
Drugs Today (Barc); 2016 Sep; 52(9):495-500. PubMed ID: 27883116
[TBL] [Abstract][Full Text] [Related]
15. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Pfaller MA; Jones RN
Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
[TBL] [Abstract][Full Text] [Related]
16. Quinolone generations: natural history or natural selection?
Ball P
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():17-24. PubMed ID: 10997595
[TBL] [Abstract][Full Text] [Related]
17. Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.
Carson C; Naber KG
Drugs; 2004; 64(12):1359-73. PubMed ID: 15200349
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of the new quinolones in the treatment of lower respiratory tract infections.
Blasi F; Tarsia P; Cosentini R; Cazzola M; Allegra L
Expert Opin Investig Drugs; 2003 Jul; 12(7):1165-77. PubMed ID: 12831351
[TBL] [Abstract][Full Text] [Related]
19. Temafloxacin: an overview.
Pankey GA
Am J Med; 1991 Dec; 91(6A):166S-172S. PubMed ID: 1662889
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of oral levofloxacin 500 mg once-daily dosage for treatment of lower respiratory tract infections and urinary tract infections: a prospective multicenter study in China.
Zhang YY; Huang HH; Ren ZY; Zheng HG; Yu YS; Lü XJ; Xiao ZK; Yang HF; Xiu QY; Chen BY; Yue HM; Hao QL; Huang JA; Ma H; Xiao W; Guo DY; Si B; Sun SH; Zhang W; Li QH; Shen HH; Duan J; Li HY; Yao WZ; Gu JM; Xia QM; Ying KJ; Liu A; Yang HP; Shi MH; Sun TY; Ding GH; Wu GM
J Infect Chemother; 2009 Oct; 15(5):301-11. PubMed ID: 19856068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
